Showing 5131-5140 of 5400 results for "".
- Valeant Pharmaceuticals Appoints New Managementhttps://practicaldermatology.com/news/20130103-valeant_pharmaceuticals_appoints_new_management/2459649/Valeant Pharmaceuticals International, Inc. named Laizer D. Kornwasser the Executive Vice President/Company Group Chairman, where he will be responsible for operations in Canada, US Neurology, and managed care and distribution, effective February
- Promius Pharma, LLC Increases Sales Force by 50 Percenthttps://practicaldermatology.com/news/20130102-promius_pharma_llc_increases_sales_force_by_50_percent/2459650/Promius Pharma, LLC is expanding its sales force to 60 from 40. Promius Pharma, which markets clinical prescription products to the US dermatology community, is in growth mode according to Rob D'Urso, head of sales and marketing for the company. “Promius Pharma is gearing up for significant growth
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice Pr
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses
- CryoShape Uses Cold to Reduce Scarshttps://practicaldermatology.com/news/20121203-cryoshape_uses_cold_to_reduce_scars/2459667/CryoShape is a patented handheld device for treating keloid and hypertrophic scars. Physicians can destroy deep tissue using an extremely cold probe that is injected directly into the scar. Treating scars with cold freezes them from the inside,
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- Jurlique Purely Bright Releases Clinical Resultshttps://practicaldermatology.com/news/20121128-jurlique_purely_bright_releases_clinical_results/2459672/Jurlique Purely Bright, a brightening system launched earlier this year, released clinical results on its product line. After 30 days, the system was clinically proven to help reduce dark spots. After 12 weeks, skin surface smoothness doubled at
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has